Inpatient Multimodal Care Improves Parkinsonian Symptoms Regardless Of Race Or Ethnicity
Objective: To verify demographic characteristics of patients with Parkinson’s disease (PD) completing a two-week inpatient multimodal intensive neurorehabilitation and care (iMINC) program and whether iMINC…Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis
Objective: To evaluate clinicians’ and patients’ views of the level of improvement in Parkinson’s disease (PD) achieved following up to two years of treatment with…Three-Year Single-Center Experience with Levodopa–Entacapone–Carbidopa Intestinal Gel in Advanced Parkinson’s Disease
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in advanced Parkinson’s Disease (APD). Background: LECIG infusion has been available in Romania since 2021.…Peripheral insulin resistance may predict exenatide treatment response in Parkinson’s disease
Objective: To explore if the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide could modify the course of Parkinson’s disease (PD) and if peripheral insulin resistance (IR) mightdifferentially impact on this. Background: Exenatide…Which Biomarker-Based Diagnostic Algorithm for Functional Motor Disorders Diagnosis?
Objective: To develop a biomarker-based diagnostic algorithm for Functional Motor Disorders (FMD) diagnosis by modeling behavioral, neurophysiological, and MRI biomarkers. Background: FMD is prevalent yet…Comparative Safety of Different Routes of Apomorphine Administration in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Objective: To assess the safety profiles of inhaled, sublingual, and subcutaneous apomorphine in patients with Parkinson’s disease (PD). Background: Apomorphine is a direct-acting D1/D2 agonist…COMT-Inhibitors Clinical Experience In Early Motor Fluctuations. Three Months Analysis Of REONPARK Study
Objective: The REONPARK study aims to evaluate COMT inhibitors (COMTi) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s disease (PD)…Dosage Optimization and Treatment Outcomes of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson’s Disease: a single center study
Objective: To optimize the dosage of foslevodopa/foscarbidopa continuous subcutaneous infusion (CSCI) therapy for Parkinson’s disease by identifying dosage differences between the continuation and discontinuation groups.…Differential Motor Cortex Compensation in Parkinson’s Disease based on Putamen Neurodegeneration Laterality: Insights from EEG and [¹⁸F]FDOPA PET/CT
Objective: To investigate differences in motor cortex compensation across Parkinson’s disease (PD) patients with different putamen neurodegeneration laterality. Background: Abnormalities in the putamen–motor cortex (M1)…Alpha-Synuclein Aggregates in the Olfactory Epithelium of Subjects with Parkinson Disease, Dementia, COVID-19, and in Aged Controls
Objective: We sought to examine whether neuroepithelial structures of the nasal cavity differ between individuals diagnosed with a Lewy body disorder vs those with COVID19…
- « Previous Page
- 1
- …
- 306
- 307
- 308
- 309
- 310
- …
- 1942
- Next Page »